Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 7:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: AstroStem-V Clear all

Conditions: Amyotrophic Lateral Sclerosis
Interventions: HB-adMSCs; Biological
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: Not listed
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Juvenile Idiopathic Arthritis (JIA)
Interventions: allogeneic Hope Biosciences adipose-derived mesenchymal stem cells, Normal Saline Solution 0.9%; Biological · Other
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 2 Years to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Stroke, Stroke, Ischemic
Interventions: HB-adMSCs; Biological
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: Not listed
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Multiple System Atrophy
Interventions: HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells; Biological
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 18 Years to 85 Years
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Primary Lateral Sclerosis, Adult, 1
Interventions: HB-adMSCs; Biological
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 18 Years and older · Male only
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Rheumatoid Arthritis
Interventions: HB-adMSCs; Biological
Lead sponsor: Hope Biosciences LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Pasadena, Texas

Conditions: Crohn Disease (CD)
Interventions: HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells, 0.9% sodium chloride; Drug
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Covid19 Pneumonia
Interventions: AstroStem-V; Drug
Lead sponsor: Nature Cell Co. Ltd.; Industry
Eligibility: 19 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Phoenix, Arizona • Dallas, Texas

Conditions: Multiple Sclerosis
Interventions: HB-adMSCs, Placebo; Biological · Drug
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Post COVID-19 Syndrome
Interventions: HB-adMSCs (allogeneic), Placebo; Biological · Other
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Traumatic Brain Injury
Interventions: HB-adMSCs; Biological
Lead sponsor: Hope Biosciences LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Congenital Muscular Dystrophy Due to Lamin A/C Mutation
Interventions: HB-adMSCs; Biological
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: Not listed
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Spinal Cord Injury at C5-C7 Level
Interventions: HB-adMSCs; Biological
Lead sponsor: Hope Biosciences LLC; Industry
Eligibility: 18 Years and older · Male only
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Alzheimer Disease
Interventions: HB-adMSCs; Biological
Lead sponsor: Hope Biosciences LLC; Industry
Eligibility: 50 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Spinal Cord Injuries
Interventions: HB-adMSCs; Biological
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Post COVID-19 Syndrome
Interventions: HB-adMSCs; Biological
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 18 Years to 65 Years
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Knee Pain Chronic, Osteo Arthritis Knee
Interventions: HB-adMSC; Biological
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: Not listed
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Erectile Dysfunction, Prostate Cancer
Interventions: Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office, Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR, Placebo in the OR, Placebo in clinic; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 40 Years to 70 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: HB-adMSCs; Biological
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: Not listed
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: COVID-19
Interventions: HB-adMSCs, Placebos; Biological · Other
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: Not listed
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Traumatic Brain Injury
Interventions: Autologous HB-adMSCs, Normal Saline; Biological · Drug
Lead sponsor: Hope Biosciences LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Houston, Texas • San Antonio, Texas

Conditions: Parkinson Disease
Interventions: Biological/Vaccine: Allogeneic HB-adMSCs, Placebo; Biological · Other
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 45 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis
Interventions: Autologous HB-adMSCs; Drug
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Cerebral Palsy
Interventions: HB-adMSCs; Biological
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 3 Years and older · Male only
U.S. locations: 1
States / cities: Sugar Land, Texas

Search by objective public record fields.

Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis

HB-adMSCs vs Placebo for the Treatment of Juvenile Idiopathic Arthritis

Individual Patient Expanded Access IND for the Treatment of Stroke

"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."

"Individual Patient Expanded Access IND to Treat Primary Lateral Sclerosis"

Phase 1/2a Clinical Trial to Assess the Safety of HB-adMSCs for the Treatment of Rheumatoid Arthritis

HB-adMSCs for the Treatment of Crohn's Disease

Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia

Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis

Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy

HBCMD01- Expanded Access for the Treatment of Congenital Muscular Dystrophy.

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Treatment of SCI

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Spinal Cord Injury

Intermediate Size Expanded Access Protocol for the Treatment of Post-COVID-19 Syndrome

Individual Patient Expanded Access IND of Autologous HB-adMSCS for the Treatment of Bilateral Knee Pain.

Stem Cells for Erectile Dysfunction Post RALP

An Expanded Access IND for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19.

Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury

Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD)

"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy